- Home
- WFRD vs PCVX Comparison
WFRD vs PCVX Comparison
Compare WFRD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFRD
- PCVX
- Stock Information
- Founded
- WFRD 1941
- PCVX 2013
- Country
- WFRD United States
- PCVX United States
- Employees
- WFRD N/A
- PCVX N/A
- Industry
- WFRD Metal Fabrications
- PCVX Biotechnology: Pharmaceutical Preparations
- Sector
- WFRD Industrials
- PCVX Health Care
- Exchange
- WFRD Nasdaq
- PCVX Nasdaq
- Market Cap
- WFRD 4.1B
- PCVX 6.0B
- IPO Year
- WFRD N/A
- PCVX 2020
- Fundamental
- Price
- WFRD $72.30
- PCVX $49.03
- Analyst Decision
- WFRD Strong Buy
- PCVX Strong Buy
- Analyst Count
- WFRD 8
- PCVX 7
- Target Price
- WFRD $86.13
- PCVX $101.67
- AVG Volume (30 Days)
- WFRD 974.0K
- PCVX 1.4M
- Earning Date
- WFRD 10-21-2025
- PCVX 11-04-2025
- Dividend Yield
- WFRD 1.39%
- PCVX N/A
- EPS Growth
- WFRD N/A
- PCVX N/A
- EPS
- WFRD 5.52
- PCVX N/A
- Revenue
- WFRD $4,970,000,000.00
- PCVX N/A
- Revenue This Year
- WFRD N/A
- PCVX N/A
- Revenue Next Year
- WFRD N/A
- PCVX N/A
- P/E Ratio
- WFRD $13.07
- PCVX N/A
- Revenue Growth
- WFRD N/A
- PCVX N/A
- 52 Week Low
- WFRD $36.74
- PCVX $27.66
- 52 Week High
- WFRD $87.63
- PCVX $98.17
- Technical
- Relative Strength Index (RSI)
- WFRD 55.45
- PCVX 69.14
- Support Level
- WFRD $68.86
- PCVX $40.14
- Resistance Level
- WFRD $76.94
- PCVX $45.90
- Average True Range (ATR)
- WFRD 2.87
- PCVX 2.30
- MACD
- WFRD -0.26
- PCVX 0.26
- Stochastic Oscillator
- WFRD 42.82
- PCVX 91.15
About WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.